ENGLISH ABSTRACT
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[Iressa in the treatment of 24 cases of advanced non-small cell lung cancer patients who had failed to previous chemotherapy].

BACKGROUND: Iressa is the inhibitor of epidemic growth factor receptor and mainly used to treat non-small cell lung cancer (NSCLC). The aim of this study is to evaluate the antitumor efficacy and toxicity of Iressa in the treatment of advanced NSCLC patients who had failed to previous chemotherapy.

METHODS: Twenty-four patiets with advanced NSCLC who were previously treated with chemotherapy received 250mg of Iressa orally once daily until disease progressing or intolerable toxicity developing. Tumor evaluation was performed before treatment. Then for every four weeks after administration they recevied the examination; after administration for sixteen weeks, examination was repeated once every eight weeks.

RESULTS: All twenty-four patients could be evaluated. One case got complete response, eight cases got partial response, three had no change and twelve had disease progression. So the response rate was 37.5%, the stable disease rate was 12.5%, and the clinical benifit rate was 50.0%. Median time to disease progressing was 87 days. All patients were followed up for two years and 1- and 2-year survival rate was 33.3% and 12.5% respectively. The common adverse effects were skin reaction and diarrhea and no grade III or IV toxicity was observed. Two cases were suspected of pulmonary interstitial changes and the treatment ended.

CONCLUSIONS: Iressa is effective in treatment of advanced NSCLC patients who had failed to previous chemotherapy and the adverse effects are tolerable. So Iressa is one of the best choice for NSCLC patients who need two or more line therapy.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app